Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
Authors: Shernan G. Holtan, Jurjen Versluis, Daniel J. Weisdorf, Jan J. Cornelissen
Journal: Journal of Clinical Oncology (2021)

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01771 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434075 Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation Shernan G. Holtan , MD1xShernan G. HoltanSearch for articles by this author; Jurjen Versluis , MD2xJurjen VersluisSearch for articles by this author; Daniel J. Weisdorf , MD1xDaniel J. WeisdorfSearch for articles by this author; and Jan J. Cornelissen , MD, PhD2xJan J. CornelissenSearch for articles by this author Show More 1Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN2Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands https://doi.org/10.1200/JCO.20.01771 First Page Full Text PDF Figures and Tables Supplements © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveOutline the design and development of approaches to select the best donor and limit the morbidity of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT).Knowledge GeneratedBalancing human leukocyte antigen matching, graft source, and other donor characteristics can assure engraftment, limit GVHD and promote immune reconstitution; all to improve HCT outcomes.RelevanceContinuing research into novel genetic features in donors, better GVHD prophylaxis, and unique GVHD treatments will make HCT safer, less toxic, and less costly.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTOptimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell TransplantationThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Shernan G. HoltanConsulting or Advisory Role: Incyte, Bristol Myers Squibb, GeneronDaniel WeisdorfConsulting or Advisory Role: Incyte, Fate TherapeuticsResearch Funding: IncyteJan J. CornelissenConsulting or Advisory Role: Daiichi SankyoNo other potential conflicts of interest were reported.